Yuji Kondo1, Ryosuke Tateishi, Haruhiko Yoshida, Masao Omata. Show Affiliations » 1. Department of Gastroenterology, University of Tokyo.
Abstract
Mesh： See more » Antiviral Agents/administration & dosageAntiviral Agents/pharmacokineticsCarcinoma, Hepatocellular/etiologyCarcinoma, Hepatocellular/prevention & controlDrug Therapy, CombinationGenotypeHepacivirus/geneticsHepatitis C, Chronic/drug therapyHepatitis C, Chronic/virologyHumansInterferon alpha-2Interferon-alpha/administration & dosageInterferon-alpha/pharmacokineticsLiver Cirrhosis/etiologyLiver Cirrhosis/prevention & controlLiver Neoplasms/etiologyLiver Neoplasms/prevention & controlPolyethylene Glycols/administration & dosagePolyethylene Glycols/pharmacokineticsRandomized Controlled Trials as TopicRecombinant ProteinsRibavirin/administration & dosageTime FactorsTreatment Outcome
Substances： See more » Antiviral AgentsInterferon alpha-2Interferon-alphaRecombinant ProteinsPolyethylene GlycolsRibavirinpeginterferon alfa-2bpeginterferon alfa-2a
Year: 2004 PMID： 15359853
Source DB: PubMed Journal: Nihon Rinsho ISSN： 0047-1852